823.23
price up icon2.41%   19.15
after-market After Hours: 824.29 1.06 +0.13%
loading
Lilly Eli Co stock is traded at $823.23, with a volume of 2.48M. It is up +2.41% in the last 24 hours and up +6.42% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$804.08
Open:
$808.41
24h Volume:
2.48M
Relative Volume:
0.63
Market Cap:
$778.66B
Revenue:
$40.86B
Net Income/Loss:
$8.37B
P/E Ratio:
89.00
EPS:
9.25
Net Cash Flow:
$-2.28B
1W Performance:
+7.42%
1M Performance:
+6.42%
6M Performance:
+4.21%
1Y Performance:
+27.68%
1-Day Range:
Value
$805.00
$824.62
1-Week Range:
Value
$760.49
$824.62
52-Week Range:
Value
$637.00
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
43,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
823.23 778.66B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
85.34 379.90B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.87 344.63B 88.82B 14.07B 19.03B 5.79
Drug Manufacturers - General icon
ABBV
Abbvie Inc
175.59 310.55B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
MRK
Merck Co Inc
98.92 251.88B 63.17B 12.15B 14.84B 4.77

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
12:16 PM

Jim Cramer Defends Eli Lilly and Company (LLY) Amid Concerns Over Drug Adherence, Cites Long-Term Health Potential - Yahoo Finance

12:16 PM
pulisher
10:01 AM

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

10:01 AM
pulisher
05:32 AM

Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar

05:32 AM
pulisher
05:03 AM

Parsons Capital Management Inc. RI Boosts Stake in Eli Lilly and Company (NYSE:LLY) - MarketBeat

05:03 AM
pulisher
05:02 AM

Verde Servicos Internacionais S.A. Takes $5.79 Million Position in Eli Lilly and Company (NYSE:LLY) - MarketBeat

05:02 AM
pulisher
02:54 AM

Eli Lilly and Company (NYSE:LLY) Cut to "Hold" at StockNews.com - MarketBeat

02:54 AM
pulisher
02:54 AM

Eli Lilly and Company (LLY) to Release Earnings on Thursday - MarketBeat

02:54 AM
pulisher
12:08 PM

Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges - Investing.com

12:08 PM
pulisher
Jan 29, 2025

Eli Lilly and Company (NYSE:LLY) Trading Up 1.9%What's Next? - MarketBeat

Jan 29, 2025
pulisher
Jan 29, 2025

Eli Lilly and Company (NYSE:LLY) Trading Up 0%Here's What Happened - MarketBeat

Jan 29, 2025
pulisher
Jan 29, 2025

Eli Lilly Stock's Correction Brings Opportunity (NYSE:LLY) - Seeking Alpha

Jan 29, 2025
pulisher
Jan 29, 2025

Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment - Indianapolis Business Journal

Jan 29, 2025
pulisher
Jan 29, 2025

Is Eli Lilly and Company (LLY) the Best Stock to Buy in 2025 for Beginners? - Insider Monkey

Jan 29, 2025
pulisher
Jan 28, 2025

Eli Lilly Bid to Upset Age-Bias Class Test Meets Leery 7th Cir. - Bloomberg Law

Jan 28, 2025
pulisher
Jan 28, 2025

Stock Quote & Chart | Eli Lilly and Company - Investors | Eli Lilly and Company

Jan 28, 2025
pulisher
Jan 28, 2025

Why Are Hedge Funds Bullish on Eli Lilly and Company (NYSE:LLY)? - Insider Monkey

Jan 28, 2025
pulisher
Jan 28, 2025

This is where: Purdue and Lilly are partnering on a shared mission to improve lives worldwide - The Persistent Pursuit

Jan 28, 2025
pulisher
Jan 28, 2025

What Does the Future Hold for Eli Lilly? - MarketBeat

Jan 28, 2025
pulisher
Jan 28, 2025

Assessing Eli Lilly: Insights From 7 Financial Analysts - Benzinga

Jan 28, 2025
pulisher
Jan 27, 2025

Eli Lilly's SWOT analysis: stock poised for growth amid challenges - Investing.com

Jan 27, 2025
pulisher
Jan 27, 2025

Eli Lilly's planned $3 billion investment in Pleasant Prairie called a ‘watershed moment’ for local economy - BizTimes Milwaukee

Jan 27, 2025
pulisher
Jan 27, 2025

Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer - GlobeNewswire Inc.

Jan 27, 2025
pulisher
Jan 27, 2025

Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief - FiercePharma

Jan 27, 2025
pulisher
Jan 27, 2025

Eli Lilly Appeal Tests Access to Age Bias, Wage Class Litigation - Bloomberg Law

Jan 27, 2025
pulisher
Jan 27, 2025

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Yahoo Finance

Jan 27, 2025
pulisher
Jan 27, 2025

Bernstein maintains Eli Lilly stock Outperform, $1,100 target - Investing.com

Jan 27, 2025
pulisher
Jan 25, 2025

Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It. - The Motley Fool

Jan 25, 2025
pulisher
Jan 24, 2025

Why Eli Lilly Stock Topped the Market Today - The Motley Fool

Jan 24, 2025
pulisher
Jan 24, 2025

Lilly’s Zepbound outpaces Wegovy as December logs 212 trial updates - BioWorld Online

Jan 24, 2025
pulisher
Jan 24, 2025

BofA reiterates Eli Lilly buy rating, $997 target - Investing.com

Jan 24, 2025
pulisher
Jan 24, 2025

BofA Securities Reiterates Buy Rating on Eli Lilly (LLY) - StreetInsider.com

Jan 24, 2025
pulisher
Jan 24, 2025

Eli Lilly stock dips on Novo Nordisk's rival drug data - Investing.com

Jan 24, 2025
pulisher
Jan 24, 2025

Is Now The Time To Put Eli Lilly (NYSE:LLY) On Your Watchlist? - Yahoo Finance

Jan 24, 2025
pulisher
Jan 23, 2025

Neurocrine Biosciences Taps Former Eli Lilly Executive to Lead Drug Development and Device Innovation - StockTitan

Jan 23, 2025
pulisher
Jan 23, 2025

Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement - Investors | Eli Lilly and Company

Jan 23, 2025
pulisher
Jan 23, 2025

Is Lilly Stock A Sell After Tumbling On Its Guidance Cut? - Investor's Business Daily

Jan 23, 2025
pulisher
Jan 23, 2025

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble? - MSN

Jan 23, 2025
pulisher
Jan 23, 2025

The Zacks Analyst Blog Eli Lilly, Exxon Mobil, Costco and Flanigan's - Zacks Investment Research

Jan 23, 2025
pulisher
Jan 22, 2025

Top Analyst Reports for Eli Lilly, Exxon Mobil & Costco - Yahoo Finance

Jan 22, 2025
pulisher
Jan 22, 2025

Why Is Eli Lilly and Company (LLY) Among the Best Large-Cap Value Stocks to Buy in 2025? - Insider Monkey

Jan 22, 2025
pulisher
Jan 22, 2025

M.E. Allison & CO. Inc. Purchases New Stake in Eli Lilly and Company (NYSE:LLY) - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases - Benzinga

Jan 22, 2025
pulisher
Jan 21, 2025

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says - Fortune

Jan 21, 2025
pulisher
Jan 21, 2025

Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound - Benzinga

Jan 21, 2025
pulisher
Jan 21, 2025

Eli Lilly: Market Overreacted (NYSE:LLY) - Seeking Alpha

Jan 21, 2025
pulisher
Jan 20, 2025

Should You Buy the Dip in Eli Lilly Stock Right Now? - AOL

Jan 20, 2025
pulisher
Jan 20, 2025

Is Eli Lilly And Co. (LLY) Splitting in the Near Future? - Insider Monkey

Jan 20, 2025
pulisher
Jan 20, 2025

Eli Lilly, Avago lead market cap stock movers on Monday - Investing.com

Jan 20, 2025
pulisher
Jan 20, 2025

Eli Lilly and Company (NYSE:LLY) Trading Down 4.1%Here's What Happened - MarketBeat

Jan 20, 2025
pulisher
Jan 20, 2025

Eli Lilly, Nvidia among Monday's market cap stock movers - Investing.com

Jan 20, 2025
pulisher
Jan 20, 2025

Lilly, Merck team with Purdue University to pioneer new drug production methods - FiercePharma

Jan 20, 2025

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general NVO
$85.34
price up icon 1.56%
drug_manufacturers_general JNJ
$152.87
price up icon 1.14%
$175.59
price up icon 0.19%
drug_manufacturers_general MRK
$98.92
price up icon 0.65%
drug_manufacturers_general NVS
$104.77
price up icon 1.79%
Cap:     |  Volume (24h):